Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Entinostat/IL-2 Combination Active in Previously Untreated Renal Cell Carcinoma

April 20th 2016

More than one-third of patients with previously untreated renal cell carcinoma responded to the combination of high-dose interleukin-2 and an investigational histone deacetylase inhibitor entinostat.

Novel Therapies Shaking Up the Renal Cell Carcinoma Landscape

April 13th 2016

Although therapeutic options for renal cell carcinoma have expanded dramatically during the past decade, oncologists are faced with considerable complexity in selecting the right course of treatment for the individual patient.

Dr. Choueiri on Using Immunotherapy to Treat RCC

April 11th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses why community oncologists should utilize immunotherapy agents to treat patients with renal cell carcinoma.

Partner's Buy-In Key to Minneapolis Urology Group's Success

April 10th 2016

At Metro Urology of Minneapolis, urologists are at the forefront of introducing new techniques and technology, especially with respect to advanced prostate cancer care.

Nivolumab Approved in Europe for Renal Cell Carcinoma

April 7th 2016

The European Commission has approved nivolumab (Opdivo) for use in previously treated patients with advanced renal cell carcinoma.

Checkpoint Inhibition New Mainstay in Metastatic RCC

April 6th 2016

Immunotherapy should be considered along with VEGF and mTOR TKIs as a highly effective treatment modality for patients with metastatic renal cell carcinoma.

Expert Discusses Evolving Role of Surgery in Kidney Cancer

April 2nd 2016

Alexander Kutikov, MD, discusses the evolving role of surgery in kidney cancer.

Novel Bladder Cancer Strategies Target PD-1/PD-L1 and VEGF Pathways

March 29th 2016

Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.

Dr. Petrylak on Immunotherapy in Bladder Cancer

March 28th 2016

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses immunotherapy agents for the treatment of patients with bladder cancer.

Immunotherapy a Mainstay in Kidney Cancer, Novel Approaches on Horizon

March 22nd 2016

Mario Sznol, MD, discusses the current state of immunotherapy in renal cell carcinoma, emerging agents and combinations in the field, and the challenges that arise with finding biomarkers.

Dr. Krajewski on Responses With PD-1 Agents in RCC

March 17th 2016

Katherine Krajewski, MD, associate director, physician, Cancer Imaging Program Fellowship, Dana-Farber Cancer Institute, assistant professor of Radiology, Harvard Medical School, discusses the range of responses seen in patients with renal cell carcinoma (RCC) who have received PD-1 agents as treatment.

Figlin Views Combination Therapy as the Key to Durable Responses in RCC

March 16th 2016

Robert A. Figlin, MD, FACP, discusses how the genomics of kidney cancer have evolved over recent years.

FDA Grants Atezolizumab Priority Review in Bladder Cancer

March 15th 2016

The FDA has granted a priority review to atezolizumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma who progressed during or after platinum-based chemotherapy in the metastatic setting, or whose disease worsened within 12 months of receiving platinum-based chemotherapy before or after surgery.

Atezolizumab Approaches FDA Approval in Bladder Cancer, But Biomarkers Remain Unclear

March 15th 2016

Matthew Galsky, MD, explains the challenges of utilizing molecular subtyping and PD-L1 as biomarkers, the impact a potential approval of atezolizumab could have in metastatic bladder cancer, possible combinations that could increase ORR, and next steps in understanding the IMvigor study.

Dr. Gulley on Checkpoint Inhibitors in Bladder Cancer

March 14th 2016

James L. Gulley, MD, PhD, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, Director, Medical Oncology Service, CCR Office of the Clinical Director, National Cancer Institute, discusses checkpoint inhibitors in bladder cancer.

Kidney Cancer Genomic Studies Reveal New Targets and Complexities

March 14th 2016

Genome sequencing studies are beginning to match distinct genomic profiles to different subtypes of kidney cancer, driving a dramatic shift in our understanding of these diseases and how to treat them.

Nivolumab Practice-Changing in RCC, But Biomarkers Still Critical for Progress

March 9th 2016

Jorge Garcia, MD, discusses CheckMate-025, the challenges with PD-1 as a biomarker, additional potential biomarkers, and why combination immunotherapy in renal cell carcinoma is still a work in progress.

Dr. Srinivasan on Targeted Therapies for Non-Clear Cell RCC

February 23rd 2016

Ramaprasad Srinivasan, MD, PhD, staff clinician, Urologic Oncology Branch, National Cancer Institute, discusses the need for targeted therapies for patients with non-clear cell renal cell carcinoma (RCC) and the types of agents these patients are likely benefit to from.

Durvalumab Granted Breakthrough Status for Bladder Cancer

February 17th 2016

The FDA has granted a breakthrough therapy designation to durvalumab as a treatment for patients with PD-L1â€“positive inoperable or metastatic urothelial bladder cancer following progression on prior treatment with a platinum-based regimen.

Expert Discusses Exciting Potential for Atezolizumab in Bladder Cancer

February 15th 2016

Arjun V. Balar, MD, discusses the phase II data demonstrating the efficacy of atezolizumab as a single agent, its potential as part of combination regimens, and planned clinical trials looking at immunotherapy in patients with metastatic bladder cancer.